We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CMS Proposes New Coverage Rule for PET Scan Needed for Alzheimer’s Drug Leqembi
CMS Proposes New Coverage Rule for PET Scan Needed for Alzheimer’s Drug Leqembi
CMS has proposed removing the national coverage determination for the positron emission tomography (PET) beta amyloid imaging needed to diagnose the onset of Alzheimer’s disease and prescribe the newly approved antiamyloid antibody drug Lequembi (lecanemab).